Medical treatment for adenomyosis and/or adenomyoma - PubMed

Review

Medical treatment for adenomyosis and/or adenomyoma

Kuan-Hao Tsui et al. Taiwan J Obstet Gynecol. 2014 Dec.

Free article

Abstract

Uterine adenomyosis and/or adenomyoma is characterized by the presence of heterotopic endometrial glands and stroma within the myometrium, >2.5 mm in depth in the myometrium or more than one microscopic field at 10 times magnification from the endometrium-myometrium junction, and a variable degree of adjacent myometrial hyperplasia, causing globular and cystic enlargement of the myometrium, with some cysts filled with extravasated, hemolyzed red blood cells, and siderophages. Hysterectomy is a "gold standard" and definitive therapy for uterine adenomyosis, and many cases of adenomyosis have been diagnosed by pathological review retrospectively. As such, the diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients, especially those who are symptomatic but have a strong desire to preserve their uterus. In our previous review, we found that the use of uterine-sparing surgery in the management of uterine adenomyosis and/or adenomyoma is still controversial, although some data support its feasibility. Conservative treatment is still needed in the group of patients that requires preservation of fertility and improvement of quality of life. However, studies focusing on the topic of medical treatment for adenomyosis are rare. In this article, current knowledge regarding the use of medical therapy for uterine adenomyosis, partly based on the understanding of endometriosis, is reviewed.

Keywords: adenomyoma; adenomyosis; medical treatment; symptom relief.

Similar articles

• Uterine-sparing surgery for adenomyosis and/or adenomyoma.

  Horng HC, Chen CH, Chen CY, Tsui KH, Liu WM, Wang PH, Chang WH, Huang BS, Sun HD, Chang TC, Chang WC, Yen MS. Horng HC, et al. Taiwan J Obstet Gynecol. 2014 Mar;53(1):3-7. doi: 10.1016/j.tjog.2014.01.001. Taiwan J Obstet Gynecol. 2014. PMID: 24767637 Review.

• Uterine adenomyoma with exophytic subserosal growth: case report of rare manifestation with image diagnosis and laparoscopic-assisted excision.

  Takeda A, Imoto S, Sugiyama C, Nakamura H. Takeda A, et al. J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):717-22. doi: 10.1016/j.jmig.2013.04.011. Epub 2013 Jun 21. J Minim Invasive Gynecol. 2013. PMID: 23796511

• Uterine adenomyosis: endovaginal US and MR imaging features with histopathologic correlation.

  Reinhold C, Tafazoli F, Mehio A, Wang L, Atri M, Siegelman ES, Rohoman L. Reinhold C, et al. Radiographics. 1999 Oct;19 Spec No:S147-60. doi: 10.1148/radiographics.19.suppl_1.g99oc13s147. Radiographics. 1999. PMID: 10517451 Review.

• Uterine adenomyoma: a clinicopathologic review of 26 cases and a review of the literature.

  Tahlan A, Nanda A, Mohan H. Tahlan A, et al. Int J Gynecol Pathol. 2006 Oct;25(4):361-5. doi: 10.1097/01.pgp.0000209570.08716.b3. Int J Gynecol Pathol. 2006. PMID: 16990713 Review.

• Adenomyosis and its variance: adenomyoma and female fertility.

  Wang PH, Su WH, Sheu BC, Liu WM. Wang PH, et al. Taiwan J Obstet Gynecol. 2009 Sep;48(3):232-8. doi: 10.1016/S1028-4559(09)60295-3. Taiwan J Obstet Gynecol. 2009. PMID: 19797011 Review.

Cited by

• Berberine attenuates hyperalgesia in mice with adenomyosis.

  Zhu B, Chen Y, Guo M, Zhang C, Huang L, Pan Q, Lin T, Lu Y, Shen X, Zhang H. Zhu B, et al. Arch Gynecol Obstet. 2022 Jul;306(1):115-125. doi: 10.1007/s00404-022-06438-y. Epub 2022 Mar 1. Arch Gynecol Obstet. 2022. PMID: 35230500

• Does any serum marker predict the ovarian endometrioma accompanied with or without deep infiltrative endometriosis?

  Horng HC, Su MH, Wang PH. Horng HC, et al. J Chin Med Assoc. 2020 Sep;83(9):797-798. doi: 10.1097/JCMA.0000000000000381. J Chin Med Assoc. 2020. PMID: 32649416 Free PMC article. No abstract available.

• Case Report: Benign Uterine Adenomyoma Metastasis in the Right Lung.

  Zhang X, Jiang H, Huang B, Wei H. Zhang X, et al. Front Surg. 2022 Feb 22;9:851147. doi: 10.3389/fsurg.2022.851147. eCollection 2022. Front Surg. 2022. PMID: 35274001 Free PMC article.

• Protective Effects of Resveratrol Against Adenomyosis in a Mouse Model.

  Zhu B, Zhang C, Shen X, Chen C, Chen X, Lu Y, Chen Y, Guo M. Zhu B, et al. Dose Response. 2023 Mar 19;21(1):15593258231164055. doi: 10.1177/15593258231164055. eCollection 2023 Jan-Mar. Dose Response. 2023. PMID: 36959835 Free PMC article.

• The Risk of Epithelial Ovarian Cancer of Women With Endometriosis May be Varied Greatly if Diagnostic Criteria Are Different: A Nationwide Population-Based Cohort Study.

  Lee WL, Chang WH, Wang KC, Guo CY, Chou YJ, Huang N, Huang HY, Yen MS, Wang PH. Lee WL, et al. Medicine (Baltimore). 2015 Sep;94(39):e1633. doi: 10.1097/MD.0000000000001633. Medicine (Baltimore). 2015. PMID: 26426652 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program